310 related articles for article (PubMed ID: 30154328)
1. New Insights in Prostate Cancer Development and Tumor Therapy: Modulation of Nuclear Receptors and the Specific Role of Liver X Receptors.
Bousset L; Rambur A; Fouache A; Bunay J; Morel L; Lobaccaro JA; Baron S; Trousson A; de Joussineau C
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30154328
[TBL] [Abstract][Full Text] [Related]
2. LXRs, SHP, and FXR in Prostate Cancer: Enemies or
Cariello M; Ducheix S; Maqdasy S; Baron S; Moschetta A; Lobaccaro JA
Nucl Recept Signal; 2018; 15():1550762918801070. PubMed ID: 30718981
[TBL] [Abstract][Full Text] [Related]
3. Absence of nuclear receptors LXRs impairs immune response to androgen deprivation and leads to prostate neoplasia.
Bousset L; Septier A; Bunay J; Voisin A; Guiton R; Damon-Soubeyrant C; Renaud Y; De Haze A; Sapin V; Fogli A; Rambur A; De Joussineau C; Kocer A; Trousson A; Henry-Berger J; Höring M; Liebisch G; Matysik S; Lobaccaro JA; Morel L; Baron S
PLoS Biol; 2020 Dec; 18(12):e3000948. PubMed ID: 33284790
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.
Yuan X; Cai C; Chen S; Chen S; Yu Z; Balk SP
Oncogene; 2014 May; 33(22):2815-25. PubMed ID: 23752196
[TBL] [Abstract][Full Text] [Related]
5. AR function in promoting metastatic prostate cancer.
Augello MA; Den RB; Knudsen KE
Cancer Metastasis Rev; 2014 Sep; 33(2-3):399-411. PubMed ID: 24425228
[TBL] [Abstract][Full Text] [Related]
6. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
7. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario.
Carruba G
J Cell Biochem; 2007 Nov; 102(4):899-911. PubMed ID: 17786930
[TBL] [Abstract][Full Text] [Related]
8. Liver X receptors interfere with the deleterious effect of diethylstilbestrol on testicular physiology.
Oumeddour A; Viennois E; Caira F; Decourbey C; Maqdasy S; Tahraoui A; Baron S; Volle DH; Lobaccaro JM
Biochem Biophys Res Commun; 2014 Apr; 446(3):656-62. PubMed ID: 24333430
[TBL] [Abstract][Full Text] [Related]
9. New insights into prostate cancer stem cells.
Chen X; Rycaj K; Liu X; Tang DG
Cell Cycle; 2013 Feb; 12(4):579-86. PubMed ID: 23370446
[TBL] [Abstract][Full Text] [Related]
10. Androgen action during prostate carcinogenesis.
Wang D; Tindall DJ
Methods Mol Biol; 2011; 776():25-44. PubMed ID: 21796518
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
[TBL] [Abstract][Full Text] [Related]
12. Liver X Receptors and Male (In)fertility.
Jarvis S; Williamson C; Bevan CL
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671745
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Hormone-Dependent Pathways in Six Human Prostate-Cancer Cell Lines: A Gene-Expression Study.
Franko A; Berti L; Guirguis A; Hennenlotter J; Wagner R; Scharpf MO; de Angelis MH; Wißmiller K; Lickert H; Stenzl A; Birkenfeld AL; Peter A; Häring HU; Lutz SZ; Heni M
Genes (Basel); 2020 Oct; 11(10):. PubMed ID: 33036464
[TBL] [Abstract][Full Text] [Related]
14. Membrane-initiated estrogen signaling in prostate cancer: A route to epithelial-to-mesenchymal transition.
Gadkar S; Nair S; Patil S; Kalamani S; Bandivdekar A; Patel V; Chaudhari U; Sachdeva G
Mol Carcinog; 2019 Nov; 58(11):2077-2090. PubMed ID: 31411358
[TBL] [Abstract][Full Text] [Related]
15. Concurrent Androgen and Estrogen Ablation and Inhibition of Steroid Biosynthetic Enzyme Treatment for Castration-resistant Prostate Cancer.
Sinha AA; Pomroy FE; Wilson MJ
Anticancer Res; 2016 Aug; 36(8):3847-54. PubMed ID: 27466486
[TBL] [Abstract][Full Text] [Related]
16. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
[TBL] [Abstract][Full Text] [Related]
17. Once and for all, LXRα and LXRβ are gatekeepers of the endocrine system.
Maqdasy S; Trousson A; Tauveron I; Volle DH; Baron S; Lobaccaro JM
Mol Aspects Med; 2016 Jun; 49():31-46. PubMed ID: 27091047
[TBL] [Abstract][Full Text] [Related]
18. Estrogen signaling and disruption of androgen metabolism in acquired androgen-independence during cadmium carcinogenesis in human prostate epithelial cells.
Benbrahim-Tallaa L; Liu J; Webber MM; Waalkes MP
Prostate; 2007 Feb; 67(2):135-45. PubMed ID: 17075824
[TBL] [Abstract][Full Text] [Related]
19. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates.
Ho SM
J Cell Biochem; 2004 Feb; 91(3):491-503. PubMed ID: 14755680
[TBL] [Abstract][Full Text] [Related]
20. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.
Schmidt LJ; Duncan K; Yadav N; Regan KM; Verone AR; Lohse CM; Pop EA; Attwood K; Wilding G; Mohler JL; Sebo TJ; Tindall DJ; Heemers HV
Mol Endocrinol; 2012 May; 26(5):716-35. PubMed ID: 22456196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
